Sign up to save your podcasts
Or
Share Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
Host: John Mascarenhas, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
View all episodes
Host: John Mascarenhas, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.